Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:12/12/2008

VIENNA, Va., Dec. 12 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (NYSE Alternext US: CVM) to its shareholders:

Dear Fellow Shareholders:

Recently we have had two pieces of important news for CEL-SCI Corporation and its shareholders. First, the U.N. World Health Organization's Agency for Research on Cancer report, in reference to the "cancer burden" wrote that "the global burden doubled in the last 30 years of the 20th Century, and it is estimated that this will double again between 2000 and 2020 and nearly triple by 2030". Cancer will soon become the Number One killer in the world, ahead of heart disease. Those increases are much greater than many people had expected and clearly make our non-toxic Multikine cancer product even more important to develop. Second, we need your help with a legislative proposal advocated by the Biotechnology Industry Organization (BIO) which would help CEL-SCI bring Multikine to market faster. Last, what percentage of people do you think will get cancer and how many of them will die from it? The answer may shake you (see below). 

    In this letter I also want to review the general status of our Multikine cancer drug:

        1. In the last few months we have hit major milestones.  We signed a
           Multikine licensing agreement with Teva Pharmaceuticals, a
           multinational pharmaceutical company, which will participate in
           and pay for part of our Phase III trial, we took delivery of our
           new manufacturing facility in Baltimore (see the pictures at
           www.cel-sci.com and click on Updated Pictures of Manufacturing
           Facility), and we extended our existing Multikine partnership with
           Orient Europharma (OEP) of Taiwan to cover a larger territory.
           OEP, like Teva, will participate in and pay for part of the Phase
           III clinical t
'/>"/>
SOURCE  CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. BioElectronics Corporation Announces Singapore and Malaysia Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... Through science fairs, workshops, kits for building ... 25 organizations will continue their work to increase awareness ... in daily life with the aid of SPIE ... 10 countries, are the first of two groups of ... the international society for optics and photonics , in ...
(Date:5/21/2013)... 2013 Savoury Systems International (SSI), a ... Braddy to Southeastern USA Sales Broker. Braddy’s new role ... in the Southeast. , In 2004 Braddy ... supplier to food processors and industrial manufacturers. Braddy ... food industry and has over 25 years of sales ...
(Date:5/21/2013)... 2013 As the R&D sector ... within the industry to deliver better products, faster. ... pharma companies often means turning big ideas into ... in collaboration with Sensidose AB and Recipharm, is ... products to market sooner. The partnership resulted in ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
... ... been selected by Prometheus as the sample collection kit for MyCeliacID™ a saliva-based genetic ... service as it solves sample collection challenges inherent with traditional collection methods which are ... ...
... CANTON, Mass., Aug. 18 Metabasis, a San Diego-based ... R&D equipment that is no longer essential to their ongoing ... and listed the premium lab and analytical equipment on the ... , , Metabasis is a biotech firm, ...
... , , ATLANTA, Aug. 18 ... medical device and cardiovascular tissue processing company, today announced the first ... FDA clearance. The surgeries were performed on pediatric patients at ... MI by Richard G. Ohye, M.D., associate professor of surgery, ...
Cached Biology Technology:DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 2DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 3Massive Inventory of Premium Lab & Analytical Equipment Now Available 2CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 2CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 3CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 4
(Date:5/22/2013)... important new details on how climate change will affect ... in the Journal of Animal Ecology . This ... and informing policymakers of how species are likely to ... is a growing recognition among biologists that climate change ... that this is going to have very important consequences ...
(Date:5/22/2013)... May 22, 2013 Early screening for prostate cancer ... testing is for women, thanks to UC Irvine research ... Chemical Society . , After more than a decade ... to clearly identify clinically usable markers for prostate cancer ... far sooner, with greater accuracy and at dramatically lower ...
(Date:5/22/2013)... pollinating insects and wild plants have slowed in recent ... by the University of Leeds and the Naturalis Biodiversity ... reductions in the diversity of species in Britain, Belgium ... But the picture brightened markedly after 1990, with a ... hoverflies and wild plants. , Professor Bill ...
Breaking Biology News(10 mins):UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... LANSING, Mich. An engineering researcher and a global ... bringing a low-cost, hand-held device to nations with limited ... Syed Hashsham, a professor of civil and environmental ... is operated using an iPod Touch or Android-based tablet ...
... that the salmon are biting less, there are less of ... researcher at the University of Oviedo (Spain). The study, ... shows a "very marked" decline in Atlantic salmon ( Salmo ... (Asturias, northern Spain), especially during the last decade, almost simultaneously ...
... Washington, DC (August 26, 2011) African Americans are four ... new study has found that a condition that occurs when ... contributes to this increased risk. The study, conducted ... appears in an upcoming issue of the Journal of ...
Cached Biology News:Hand-held unit to detect cancer in poorer countries 2The same number of fishermen, but less salmon in Spanish rivers 2
Ready-to-use solution....
ready-to-use solution...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Clone/PAD: ZMD.420. Immunogen: ... Specificity: Specific for the ... Reactivity: Human (positive control: ... Based on sequence homology reactivity ...
Biology Products: